XML 42 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaboration and Contract Research Agreements (Tables)
 12 Months Ended
Dec. 31, 2012
Revenues [Abstract]  
Collaboration revenue
The collaboration revenue the Company earned from Bayer HealthCare is detailed below:
 
 
Year ended December 31,
Bayer HealthCare Collaboration Revenue
 
2012
 
2011
 
2010
Cost-sharing of Regeneron EYLEA development expenses
 
$
37,191

 
$
33,681

 
$
45,509

Substantive milestone payments
 
25,000

 
 
 
20,000

Regeneron's net profit in connection with commercialization of EYLEA outside the United States
 
—

 
 
 
 
Recognition of deferred revenue related to up-front and other milestone payments
 
7,908

 
9,390

 
9,884

 
 
$
70,099

 
$
43,071

 
$
75,393
Collaboration revenue with related party
The collaboration revenue related to ZALTRAP that the Company earned from Sanofi is detailed below:
 
 
Year ended December 31,
ZALTRAP Collaboration Revenue:
 
2012
 
2011
 
2010
Regeneron's share of losses in connection with commercialization of ZALTRAP
 
$
(25,634
)
 
$
(9,341
)
 
 
Substantive milestone payment
 
50,000

 
 
 
 
Reimbursement of Regeneron research and development and other expenses
 
12,821

 
16,891

 
$
16,483

Recognition of deferred revenue related to up-front payments
 
11,149

 
9,932

 
9,932

 
 
$
48,336

 
$
17,482

 
$
26,415